vs
Amphastar Pharmaceuticals, Inc.（AMPH）とEsperion Therapeutics, Inc.（ESPR）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $168.4M、Esperion Therapeutics, Inc.の約1.1倍）。Esperion Therapeutics, Inc.の前年同期比売上増加率が高い（143.7% vs -1.8%）。過去8四半期でEsperion Therapeutics, Inc.の売上複合成長率が高い（10.6% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Esperion Therapeutics, Inc.は米国の上場製薬企業で、低密度リポタンパク質コレステロールを低下させる経口投与可能な小分子医薬品ベンペドイン酸の開発に注力しています。本社はミシガン州アナーバーに位置し、脂質異常症治療分野におけるイノベーティブな医薬品開発を進めています。
AMPH vs ESPR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $168.4M |
| 純利益 | $24.4M | — |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 50.6% |
| 純利益率 | 13.3% | — |
| 売上前年比 | -1.8% | 143.7% |
| 純利益前年比 | -35.7% | — |
| EPS（希薄化後） | $0.51 | $0.32 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $168.4M | ||
| Q3 25 | $191.8M | $87.3M | ||
| Q2 25 | $174.4M | $82.4M | ||
| Q1 25 | $170.5M | $65.0M | ||
| Q4 24 | $186.5M | $69.1M | ||
| Q3 24 | $191.2M | $51.6M | ||
| Q2 24 | $182.4M | $73.8M | ||
| Q1 24 | $171.8M | $137.7M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-31.3M | ||
| Q2 25 | $31.0M | $-12.7M | ||
| Q1 25 | $25.3M | $-40.5M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-29.5M | ||
| Q2 24 | $37.9M | $-61.9M | ||
| Q1 24 | $43.2M | $61.0M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 50.6% | ||
| Q3 25 | 13.2% | -11.4% | ||
| Q2 25 | 24.2% | 8.6% | ||
| Q1 25 | 21.9% | -34.0% | ||
| Q4 24 | 24.2% | -6.4% | ||
| Q3 24 | 29.8% | -31.0% | ||
| Q2 24 | 30.3% | 3.5% | ||
| Q1 24 | 27.9% | 52.5% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -35.9% | ||
| Q2 25 | 17.8% | -15.4% | ||
| Q1 25 | 14.8% | -62.2% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -57.2% | ||
| Q2 24 | 20.8% | -83.9% | ||
| Q1 24 | 25.1% | 44.3% |
| Q4 25 | $0.51 | $0.32 | ||
| Q3 25 | $0.37 | $-0.16 | ||
| Q2 25 | $0.64 | $-0.06 | ||
| Q1 25 | $0.51 | $-0.21 | ||
| Q4 24 | $0.74 | $-0.14 | ||
| Q3 24 | $0.78 | $-0.15 | ||
| Q2 24 | $0.73 | $-0.33 | ||
| Q1 24 | $0.81 | $0.34 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $167.9M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $-302.0M |
| 総資産 | $1.6B | $465.9M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $167.9M | ||
| Q3 25 | $276.2M | $92.4M | ||
| Q2 25 | $231.8M | $86.1M | ||
| Q1 25 | $236.9M | $114.6M | ||
| Q4 24 | $221.6M | $144.8M | ||
| Q3 24 | $250.5M | $144.7M | ||
| Q2 24 | $217.8M | $189.3M | ||
| Q1 24 | $289.6M | $226.6M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $-302.0M | ||
| Q3 25 | $776.7M | $-451.4M | ||
| Q2 25 | $757.5M | $-433.5M | ||
| Q1 25 | $751.3M | $-426.2M | ||
| Q4 24 | $732.3M | $-388.7M | ||
| Q3 24 | $727.7M | $-370.2M | ||
| Q2 24 | $713.3M | $-344.2M | ||
| Q1 24 | $672.4M | $-294.3M |
| Q4 25 | $1.6B | $465.9M | ||
| Q3 25 | $1.7B | $364.0M | ||
| Q2 25 | $1.6B | $347.1M | ||
| Q1 25 | $1.6B | $324.0M | ||
| Q4 24 | $1.6B | $343.8M | ||
| Q3 24 | $1.5B | $314.1M | ||
| Q2 24 | $1.5B | $352.3M | ||
| Q1 24 | $1.6B | $373.1M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $45.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | — |
| FCFマージンFCF / 売上 | 13.4% | — |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.0% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $45.2M | ||
| Q3 25 | $52.6M | $-4.3M | ||
| Q2 25 | $35.6M | $-31.4M | ||
| Q1 25 | $35.1M | $-22.6M | ||
| Q4 24 | $29.0M | $-35.0M | ||
| Q3 24 | $60.0M | $-35.3M | ||
| Q2 24 | $69.1M | $-7.2M | ||
| Q1 24 | $55.3M | $53.8M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $-35.5M | ||
| Q2 24 | $63.1M | $-7.3M | ||
| Q1 24 | $46.5M | $53.8M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | -68.7% | ||
| Q2 24 | 34.6% | -9.9% | ||
| Q1 24 | 27.1% | 39.0% |
| Q4 25 | 4.5% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.1% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 0.88× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
